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Abstract
Background: An imbalance in the generation of pro-inflammatory leukotrienes, and counter-regulatory lipoxins is 
present in severe asthma. We measured leukotriene B4 (LTB4), and lipoxin A4 (LXA4) production by alveolar 
macrophages (AMs) and studied the impact of corticosteroids.
Methods: AMs obtained by fiberoptic bronchoscopy from 14 non-asthmatics, 12 non-severe and 11 severe asthmatics 
were stimulated with lipopolysaccharide (LPS,10 μg/ml) with or without dexamethasone (10-6M). LTB4 and LXA4 were 
measured by enzyme immunoassay.
Results: LXA4 biosynthesis was decreased from severe asthma AMs compared to non-severe (p < 0.05) and normal 
subjects (p < 0.001). LXA4 induced by LPS was highest in normal subjects and lowest in severe asthmatics (p < 0.01). 
Basal levels of LTB4 were decreased in severe asthmatics compared to normal subjects (p < 0.05), but not to non-severe 
asthma. LPS-induced LTB4 was increased in severe asthma compared to non-severe asthma (p < 0.05). Dexamethasone 
inhibited LPS-induced LTB4 and LXA4, with lesser suppression of LTB4 in severe asthma patients (p < 0.05). There was a 
significant correlation between LPS-induced LXA4 and FEV1 (% predicted) (rs = 0.60; p < 0.01).
Conclusions: Decreased LXA4 and increased LTB4 generation plus impaired corticosteroid sensitivity of LPS-induced 
LTB4 but not of LXA4 support a role for AMs in establishing a pro-inflammatory balance in severe asthma.
Introduction
Patients with asthma are usually well-controlled with
inhaled corticosteroids (CS) and long-acting β2-agonists,
but a minority of patients described as severe asthma
continues to experience uncontrolled asthma in spite of
these treatments. Patients with severe asthma suffer
greater morbidity, face a higher risk of asthma death, and
consume a greater proportion of health resources than
other non-severe asthma patients [1,2]. One feature of
s e v e r e  a s t h m a  i s  t h e  p r e s e n c e  o f  a i r w a y  i n f l a m m a t i o n
despite corticosteroid therapy, often characterised by the
persistence of eosinophilic inflammation and the pres-
ence of neutrophils[3,4]. Persistent symptoms with fre-
quent exacerbations of asthma despite corticosteroid
therapy also indicate the possibility that CS may not be as
effective in patients with severe asthma. The presence of
reduced CS sensitivity in severe asthma is supported by
the finding that release of cytokines from peripheral
blood mononuclear cells and alveolar macrophages is less
suppressible by dexamethasone than those from non-
severe asthma patients[5,6].
Lipid mediators of the 5-lipoxygenase pathway such as
cysteinyl-leukotrienes are implicated as mediators of air-
way bronchoconstriction and eosinophilic inflammation
in asthma; another product, leukotriene B4 (LTB4), has
also been implicated, particularly in view of its chemoat-
tractant and activating properties for neutrophils [7].
Similar to LTs, lipoxins (LXs) are products of arachidonic
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acid metabolism, yet LXs are generated via interactions
between 5- and 15-lipoxygenases or 5- and 12-lipoxyge-
nases to form structurally distinct compounds that pro-
mote the resolution of inflammation. Thus, LXs are
counter-regulatory to the cysteinyl-leukotrienes and
LTB4 [8]. The possibility that dysregulation of the balance
among these arachidonic acid products might contribute
to the persistent inflammation in severe asthma has been
supported by the demonstration of an increased genera-
tion of cysteinyl-leukotrienes with impaired biosynthesis
of lipoxin A4 (LXA4) from whole blood of patients with
severe asthma compared to non-severe asthma
patients[9]. In addition, LXA4 levels in bronchoalveolar
l a v a g e  f l u i d  o f  p a t i e n t s  w i t h  s e v e r e  a s t h m a  f r o m  t h e
NHLBI Severe Asthma Research Program were
decreased when compared to non-severe asthma patients
[10].
We determined whether an imbalance in pro-inflam-
matory LTB4 and anti-inflammatory LXA4 in the lungs of
patients with severe asthma could be reflected in the for-
mation of these products from alveolar macrophages
(AMs). We also determined whether there would also be
a differential suppressibility of these mediators that
reflect different effects in asthma.
Methods
Patients
Patients with asthma were recruited from the Asthma
Clinic of the Royal Brompton Hospital, London. Severe
asthma patients underwent the Royal Brompton severe
asthma protocol, in order to confirm the diagnosis and to
maximise treatments[11]. All patients showed either an
improvement in baseline FEV1 of ≥12% over baseline val-
ues after inhalation of 400 μg of salbutamol aerosol, or
the presence of bronchial hyperresponsiveness defined by
methacholine PC20 of < 4 mg/ml. Current and ex-smokers
of >5 pack-years were excluded. Severe asthmatics were
defined according to the American Thoracic Society
major criteria of needing either continuous or near-con-
tinuous oral corticosteroids or high dose inhaled corti-
costeroids (2,000 μg beclomethasone-equivalent per day
or more) or both in order to achieve a level of mild-mod-
erate persistent asthma, and by 2 or more minor criteria
of asthma control[12]. Patients who had well-controlled
asthma defined by the lack of day-time or nocturnal
symptoms and no need for reliever medications while
using ≤ 800 μg of inhaled beclomethasone-equivalent per
day were enrolled into the non-severe asthma group.
Healthy volunteers with no diagnosis of asthma and with
a negative PC20 (>16 mg/ml), using no medications and
never-smokers, were also recruited. All participants gave
informed consent to a protocol approved by the Ethics
Committee of Royal Brompton & Harefield NHS Trust/
National Heart & Lung Institute.
Fiberoptic bronchoscopy
All asthmatic subjects received 5 mg of nebulised salbuta-
mol before the procedure. Fibreoptic bronchoscopy was
performed using topical anesthesia with lignocaine and
intravenous sedation with midazolam. Warmed 0.9%
NaCl solution (50 ml × 4) was instilled into the right mid-
dle lobe and recovery of broncho-alveolar lavage (BAL)
fluid was carried out by gentle hand suction.
Alveolar macrophage isolation
BAL cells were centrifuged (500 × g for 10 minutes) and
washed with Hanks' balanced salt solution (HBSS). They
were resuspended in culture media (RPMI with 0.5% fetal
calf serum, antibiotics and L-glutamine) and counted
using Kimura dye. Cytospins were prepared and stained
with Diff Quick (Harleco, Gibbstown, NJ) stain for differ-
ential cell count. 5×105 macrophages were isolated by
plastic adhesion and stimulated for 18 hours with
lipopolysaccaride (LPS, 10 μg/ml) in the presence or
absence of dexamethasone (Dex, 10-6 M). Supernatants
were aliquoted and coded. These de-identified materials
were analysed in a separate laboratory for LTB4 and LXA4
by enzyme immunoassay (Cayman Chemical, Ann Arbor,
Mich; Neogen, Lexington, KY). The stimulated formation
of LTB4  and LXA4  was calculated as the difference
between the total amount present with LPS and the basal
amounts without LPS.
Validation of Immunoreactive LXA4 by Addition of 
Authentic LXA4
As the absolute amounts of LXA4 in the macrophage
supernatant samples were too low for detection by physi-
cal methods, we validated our immunoassay measure-
ments by purposefully adding 20-30 pg of authentic LXA4
to selected sample aliquots and then measuring immuno-
reactive LXA4 l e v e l s  i n  b o t h  n e a t  a n d  s p i k e d  s a m p l e s .
Addition of authentic LXA4 increased the total amount of
LXA4 (endogenous plus exogenous) above the lower lim-
its of detection for the ELISA. Neat and spiked samples
displayed only minor variance in the amount of endoge-
nous LXA4.
Data analysis
Results are expressed as means ± SEM. The differences in
LTB4  and LXA4  generated at baseline were compared
using one-way analysis of variance with Dunn's multiple
comparison test. Differences between LPS and LPS plus
dexamethasone treatment were analysed using Wilcoxon
paired t-tests and in this case differences between groups
were compared using Mann-Whitney t-test. CorrelationsBhavsar et al. Respiratory Research 2010, 11:71
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were performed using Spearman's rank tests. p < 0.05 was
taken as significant.
Results
Severe asthmatics had more severe airflow obstruction (p
< 0.05) and bronchial hyperresponsiveness (p < 0.05)
compared to non-severe asthmatics (Table 1). They were
also on higher doses of inhaled corticosteroids (p < 0.05).
BAL yielded fewer cells from severe asthmatics compared
to non-severe asthmatics (p = 0.06), but there were pro-
portionately more eosinophils (p < 0.05) and neutrophils
(p < 0.05) with fewer macrophages (p < 0.01) in severe
asthma compared to non-severe asthma.
Baseline and LPS-stimulated generation of LXA4
Low levels of LXA4 were generated by AMs in culture.
The baseline LXA4 from AMs obtained from normal sub-
jects was higher than that from both non-severe (p <
0.05) and severe asthmatics (p < 0.01; Figure 1A). There
was a significant difference between non-severe and
severe asthmatics (p < 0.05) with a three-fold higher base-
line level in non-severe asthmatics. The LXA4 production
induced by LPS is shown as the increment in LXA4 above
baseline (Figure 1B). There was a small but significant
increase in LPS-induced LXA4 levels in all three groups
(Figure 1B), with the lowest amounts in severe compared
to non-severe asthma (p < 0.01) and to normal subjects (p
< 0.001).
There was a negative correlation between baseline
LXA4 levels in asthmatic patients and the percentage of
neutrophils in the BAL (rs = - 0.42, p < 0.05), and a posi-
tive correlation between LPS-induced LXA4 levels from
asthmatic patients and FEV1 (% predicted; r = 0.60, p <
0.01). In addition, there was a negative correlation
between percentage neutrophils in the BAL and FEV1 (rs
= -0.65, p < 0.001).
Basal and LPS-stimulated generation of LTB4
The basal level of LTB4 from AMs obtained from normal
subjects was higher than that from both non-severe (p <
0.05) and severe asthmatics (p < 0.05; Figure 2A), with no
significant differences between non-severe and severe
asthmatics. The LTB4  production induced by LPS is
shown as increments in LTB4 above baseline (Figure 2B).
LPS induced LTB4 generation in all three groups (p <
0.05), but the increase in LTB4 in severe asthma patients
was 5-fold greater than in non-severe asthmatics (p <
0.05; Figure 2B).
Table 1: Characteristics of subjects
Normal Non-Severe asthma Severe asthma
n 14 12 11
Age (yr) 21 ± 0.4 43 ± 3 47 ± 3
Atopy 0/14 11/12 9/11
M/F 12/2 7/5 4/7
FEV1 (% Predicted) 98 ± 3 85 ± 3 58 ± 6*
PC20 (mg/ml) >16 5.73 ± 2.7 0.64 ± 0.14*
Inhaled corticosteroid
BDP equivalent (μg/day)
0 527 ± 239
(n = 6)
2400 ± 414*
(n = 11)
Oral prednisolone (mg/day) 00 1 9 . 1  ±  3 . 2
(n = 6)
Total BAL Cells
(× 106)
9.19 ± 1.4 8.36 ± 0.8 6.1 ± 0.99
BAL-Macs (×106) 9.02 ± 1.32 8.17 ± 0.76 5.81 ± 1.00
BAL-Neu (×106) 0.1 ± 0.03 0.063 ± 0.016 0.15 ± 0.03
BAL-Eos (×106) 0.018 ± 0.012 0.026 ± 0.012 0.07 ± 0.03
BAL-Mac (%) 97.9 ± 0.5 97.8 ± 0.4 92.9 ± 1.5**
BAL-Neu (%) 1.03 ± 0.3 0.8 ± 0.2 3 ± 0.7*
BAL-Eos (%) 0.21 ± 0.09 0.29 ± 0.14 1.4 ± 0.55*
Abbreviations: M = Male; F = Female; BAL = Bronchoalveolar lavage; BDP = Beclomethasone dipropionate; Neu = neutrophils; Eos = 
eosinophils; Mac = macrophage. Data shown as mean ± SEM. *p < 0.05; **p < 0.01 compared to non-severe asthma.Bhavsar et al. Respiratory Research 2010, 11:71
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Corticosteroid suppression of LXA4. and LTB4
Dexamethasone suppression of LPS-initiated LXA4 was
significant in all three groups (p < 0.05), with no signifi-
cant differences between the groups (Figure 3). Dexame-
thasone suppression of LTB4 was observed in all three
groups: normal subjects (LPS: 102 ± 23 versus LPS and
dexamethasone: 11.6 ± 7.7 pg/ml, p < 0.05); non-severe
asthmatics (183 ± 122 versus 21.4 ± 22 pg/ml, p < 0.05)
and severe asthmatics (230 ± 102 versus 60 ± 32 pg/ml, p
< 0.01). When the suppression was expressed as a per-
centage of LPS-induced eicosanoid production, there was
no significant differences observed between normal and
non-severe asthmatics with ~90% suppression. However,
there was a lesser degree of suppression in severe asth-
matics (Figure 4).
In macrophages from normal subjects, the ratio of LTB4
to LXA4 (using pg/ml) was unchanged after exposure to
LPS or to LPS plus dexamethasone. In non-severe asth-
matics, both LPS and LPS plus dexamethasone gave an
increased LTB4/LXA4 ratio, but only in severe asthmatics
was the increase induced by LPS and dexamethasone sig-
nificantly greater than that induced by LPS alone (p <
0.05) (Figure 5). In addition, LTB4/LXA4 ratios after LPS
and dexamethasone were significantly greater in severe
asthmatics compared to non-severe asthmatics (p < 0.05)
Figure 1 Panel A: Individual levels of LXA4 in supernatants of al-
veolar macrophages before and after lipopolysaccharide (LPS) 
from normal subjects (n = 14), non-severe asthmatics (n = 12) and 
severe asthmatics (n = 11). In the asthmatic groups, closed symbols 
indicate those on regular treatment with inhaled and/or oral corticos-
teroids. Panel B: Mean levels of LXA4 induced by LPS (level after LPS mi-
nus basal level) in the 3 groups. Data shown as mean ± SEM.
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Figure 2 Panel A: Individual levels of LTB4 in supernatants of alve-
olar macrophages before and after lipopolysaccharide (LPS) from 
normal subjects (n = 9), non-severe asthmatics (n = 9) and severe 
asthmatics (n = 8). In the asthmatic groups, closed symbols indicate 
those on regular treatment with inhaled and/or oral corticosteroids. 
Panel B: Mean levels of LPS-stimulated LTB4 represented by the differ-
ence between LTB4 levels with LPS and the basal level of LTB4 in the 3 
groups. Data shown as mean ± SEM.
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as a result of both an increase in LTB4 and a decrease in
LXA4 compared to normal subjects.
Discussion
We have shown that the basal generation of the proin-
flammatory LTB4 and the anti-inflammatory LXA4 were
both lower in cultured AMs from severe asthmatics com-
pared to those from non-asthmatics, while only LXA4 was
lower in severe asthmatics compared to non-severe asth-
matics. The LPS induced formation of LTB4 was higher in
severe asthma compared to non-severe asthma and nor-
mal subjects, while the LPS induced production of LXA4
was significantly impaired in severe asthmatics compared
to normal subjects, but to a similar extent as in non-
severe asthma patients. The overall effect of LPS stimula-
tion was a net pro-inflammatory balance in terms of
enhanced generation of LTB4, and a decrease in LXA4
compared to AMs from normal subjects. In addition,
while the LPS-induced LTB4 was largely suppressed by
dexamethasone, it was only partly suppressed in AMs
from severe asthma patients; by contrast, induced gener-
ation of LXA4 was suppressed in all three groups. There-
fore, the overall balance of these 2 lipid mediators in
severe asthma was in favour of an overall pro-inflamma-
tory response through both increased production and
relative corticosteroid insensitivity of LTB4 and decreased
levels of LXA4 in severe asthmatics, as illustrated by the
LTB4 to LXA4 ratios.
Human AMs can generate both 5-lipoxygenase and 15-
lipoxygenase derived eicosanoids, including LTB4  and
Figure 3 Individual levels of LXA4 measured after LPS in the ab-
sence or presence of dexamethasone (10-6 M) from alveolar mac-
rophages stimulated by LPS from normal subjects (n = 14), non-
severe asthmatics (n = 12) and severe asthmatics (n = 11). In the 
asthmatic groups, closed symbols indicate those on regular treatment 
with inhaled and/or oral corticosteroids. Data shown as mean ± SEM.
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Figure 4 Individual levels of LTB4 measured after LPS in the ab-
sence or presence of dexamethasone (10-6 M) from alveolar mac-
rophages stimulated by LPS in normal subjects (n = 9), non-
severe asthmatics (n = 9) and severe asthmatics (n = 8). In the asth-
matic groups, closed symbols indicate those on regular treatment with 
inhaled and/or oral corticosteroids. Data shown as mean ± SEM. Panel 
C. Mean degree of suppressibility of LXA4 and LTB4 release by dexame-
thasone. Data is expressed as % of LXA4 or LTB4 release after exposure 
to LPS (level after LPS minus basal level) and shown as mean ± SEM.
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LXA4, from endogenous sources of arachidonic acid[13].
LXA4 generation from endogenous stores is low, but LX
biosynthesis can be amplified by select TH2 cytokines,
namely interleukin-4 and interleukin-13 [14,15]. In addi-
tion, exogenous LTA4 can be converted by AMs to more
substantial amounts of LXs [16], as would occur during
transcellular biosynthesis with LTA4 donation from one
cell to a second cell for enzymatic conversion by either
12- or 15-lipoxygenase to LXs. Our studies are the first to
document both LTB4 and LXA4 generation from human
AMs from asthmatic subjects. Although the levels of
LXA4 are low, they were detected reproducibly, validated
with authentic material and picogram quantities of LXs
are biologically active in resolving inflammation
(reviewed in reference [17]). Interestingly, when the data
was expressed as a ratio of pro-inflammatory LTB4 to
anti-inflammatory LXA4, there was an increased pro-
inflammatory imbalance when the macrophages from
both asthmatic groups were exposed to LPS, and this was
not reversed by corticosteroids. Indeed, in macrophages
from severe asthma, this pro-inflammatory ratio favour-
ing LTB4 over LXA4 was further unbalanced by dexame-
thasone.
Our results indicate that the pulmonary macrophage
can be an important source of lipid mediators, and that
differences in LTB4  and LXA4  between the asthmatic
groups are in general agreement with recent studies that
have examined levels in whole blood[9,18] and BAL fluids
[10]. In the study of Wenzel et al, levels of LTB4 in BAL
fluid from severe asthma were the highest compared to
levels from moderate symptomatic asthma patients and
normals [19]. This indicates that the baseline contribu-
tion of LTB4 from macrophages is unlikely to explain this
increased levels found in BAL of severe asthma patients;
however, following ex vivo stimulation of macrophages
from severe asthma patients, greater levels of LTB4 were
released compared to non-severe asthma patients. Using
a similar method as our study to distinguish severe from
non-severe asthma, a deficiency in both baseline and
divalent cation ionophore-stimulated production of
LXA4 in whole blood of patients with severe asthma com-
pared to moderate asthma was established, while the pro-
duction of cysteinyl-leukotrienes and LTB4  were
increased[9]. In addition, similar findings have been
reported in airway fluids for the levels of these lipid medi-
ators; thus, an increase in LTB4 levels was found in the
supernatant of induced sputum of severe asthma patients
compared to non-severe asthma. In these same samples,
LXA4  levels were highest in the mild asthma
group[20,21]. Moreover, LXA4 levels in BAL fluids from
patients with severe asthma recruited in the NHLBI
Severe Asthma Research Program are decreased com-
pared to non-severe asthma patients, and BAL cells from
severe asthma patients had increased 5-LO and
decreased 15-LO expression [10]. These results are in line
with the current observation of reduced basal and LPS-
stimulated production of LXA4  from alveolar mac-
rophages of patients with severe asthma. In conjunction
with the large number of alveolar macrophages in healthy
and asthmatic lung, these observations provide support
to the idea that the alveolar macrophage is a likely impor-
tant source of LXA4 in human airways.
There have been very few studies of the effect of LPS on
human macrophages in terms of LT and LX generation.
Brief exposure of murine macrophages to LPS can prime
them to increase LT synthesis in response to an activating
stimulus such as immune complexes or divalent cation
ionophore A23187[22], an observation that has been sub-
sequently shown in human AMs [23]. On the other hand,
prolonged exposure to LPS impaired the capacity of rat
macrophages to produce LTs in response to stimulating
agents, a process that was due to the production of inhib-
itory substances such as nitric oxide [24,25]. LPS can
induce human AM phagocytosis of apoptotic cells, but
AMs from subjects with severe asthma display defective
clearance mechanisms and lower levels of PGE2 and 15-
hydroxyeicosatetraenoic acid formation in response to
LPS[26]. Both PGE2 and 15-HETE can play pivotal roles
in establishing LX biosynthesis [27,28].
Differences in basal LTB4 from AMs have not been pre-
viously observed between asthma and normal atopic or
non-atopic control subjects[29], or those with nocturnal
Figure 5 Effect of LPS (Stim) and LPS plus dexamethasone (LPS/
Dex) on the ratio of LTB4 to LXA4 from alveolar macrophages. In 
both asthmatic groups, the ratio of released LTB4 to released LXA4 is in-
creased after LPS and this is not reversed in the presence of dexame-
thasone. *p < 0.05 compared to baseline (base) within each group; +p 
< 0.01 compared to LPS/Dex of normal subjects. Data shown as shown 
as mean ± SEM.
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asthma [30]. However, asthmatic subjects in these studies
would not have met the NHLBI Severe Asthma Research
Program's criteria for severe asthma [2]. Regarding cal-
cium ionophore-induced LTB4 biosynthesis by AMs, one
study reported increased LTB4  generation by cells in
asthma compared to non-asthmatics [31], while another
study did not report any significant differences[29]. Our
study shows reduced baseline LTB4 in non-severe asthma
and no significant differences in stimulated production
by LPS compared to non-asthmatics. Because LTB4 bio-
synthesis by AMs in vitro can be modulated by environ-
mental factors in vivo, such as cigarette smoking [32],
smokers were excluded from the study.
Glucocorticoids have been shown to inhibit LT genera-
tion through inhibition of phospholipase A2  activity
[33,34]. Chronic oral corticosteroid therapy may lead to a
suppression of eicosanoid biosynthesis and could under-
lie the baseline reduction in LXA4 and LTB4 observed in
the macrophages from patients with severe asthma. Both
LTB4 and LXA4 stimulated by calcium ionophore in the
circulating neutrophil was reduced in corticosteroid-
dependent asthmatics who were on oral prednisolone
[35]. However, as far as the AM is concerned, there was
no significant inhibition of LTB4 from AMs of normal
subjects treated with oral prednisolone despite the fact
that direct incubation of these cells with dexamethasone
leads to an inhibition of basal and calcium ionophore
triggered formation of LTB4 [36]. Other work also indi-
cate that oral short-term treatment with prednisone does
not inhibit the levels of the eicosanoids, PGD2, 5-HETE
and LTE4, in BAL from asthmatic subjects at baseline or
after allergen challenge [37]. However, ex-vivo treatment
of BAL cells with prednislone did cause inhibition of
LTB4 and thromboxane generation. Similarly, in the work
of Wenzel et al, a single dose of oral prednisone inhibited
LTB4 release from alveolar macrophages from patients
with nocturnal asthma but not from those without noc-
turnal asthma [30]. Only half of the patients with severe
asthma in this study were on oral corticosteroid therapy
and there was no significant differences in terms of LPS-
induced LTB4 or LXA4 or of dexamethasone-induced sup-
pression between macrophages of severe asthma patients
who were on prednisolone versus those not on predniso-
lone. Similarly, in the non-severe asthma group, there was
no difference in terms of LPS-induced LTB4 or LXA4 or of
dexamethasone-induced suppression between mac-
rophages of non-severe asthma patients who were on
daily inhaled corticosteroids versus those not on inhaled
corticosteroids. However, the influence of long-term oral
or inhaled corticosteroid therapy, as contrasted to short-
term, on this ex-vivo  production of arachidonic acid-
derived mediators cannot be entirely excluded.
We have elected to group our asthmatic patients as
non-severe and severe asthma patients on the basis of the
definition of severe asthma proposed by the ATS [12].
This definition of severe asthma is based on the lack of
control of asthma despite taking maximal anti-inflamma-
tory treatments with corticosteroids, while the non-
severe asthma patients were those on no or only low-dose
inhaled corticosteroids. We observed that there was rela-
tive CS insensitivity of LTB4 generation but not of LXA4
from AMs of patients with severe asthma. Previously, no
differences in CS sensitivity of AMs in terms of calcium
ionophore induced LTB4 from asthmatics as compared to
non-asthmatic macrophages have been reported[29]. In a
previous study, we have shown that AMs from patients
with severe asthma demonstrate a reduced sensitivity to
dexamethasone in terms of LPS-induced release of pro-
inflammatory cytokines [5].
Our data on LXA4 is one of the first regarding its stimu-
lated production by LPS, and its suppression by dexame-
thasone. Levels of anti-inflammatory LXs were low in
severe asthmatics, and did not increase in response to
LPS stimulation, further increasing the disparity between
severe asthmatics and non-severe asthmatics in the levels
of these mediators. Moreover, dexamethasone sup-
pressed LPS-induced increases in LXA4 in all groups.
This differential response of AMs from severe asthmatics
vis-a-vis LTB4 and LXA4 and the effect of corticosteroids
(increased LTB4 in response to LPS and impaired CS sup-
pression of the rise in LTB4 vs. little change in LXA4 in
response to LPS and unimpaired CS suppression of LXA4
levels) may contribute to persistent airway neutrophilic
inflammation since LXA4  can inhibit LTB4-induced
chemotaxis, adhesion and transmigration[17]. This
potential role of LXA4 in regulating neutrophil chemot-
axis is supported by the inverse relationship between
baseline LXA4 and the percentage of neutrophils in bron-
choalveolar lavage fluid.
Lipoxins are a distinct class of eicosanoids with anti-
inflammatory properties at subnanomolar concentra-
tions. Thus, although the basal and stimulated levels of
LXA4 from alveolar macrophages are in low picogram
amounts, these levels would be predicted to have pro-
resolving actions for airway inflammation (reviewed in
[17]. In support of the protective effect of LXA4, we found
a positive correlation between LPS-induced LXA4 and
lung function as represented by FEV1. Indirectly, this pro-
tection in lung function may occur through an effect on
neutrophilic inflammation, since there was an inverse
correlation between BAL neutrophilia and FEV1. LXA4
can inhibit LTB4-initiated chemotaxis, adhesion and
transmigration. In addition, LXA4 inhibits eosinophilic
allergic inflammation [38]. Thus, a possible imbalance inBhavsar et al. Respiratory Research 2010, 11:71
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LTB4 and LXA4 in the airways would serve to increase air-
way neutrophil and eosinophil accumulation and activa-
tion. Interestingly, a similar imbalance between LT and
LX generation is present in scleroderma lung disease [39]
and decreased lipoxin production has also been reported
in inflammatory bowel disease [40].
One of the potential limitations of our work regards the
relative age of the healthy control group that were
younger than the asthma groups. Generation of LXA4 can
decrease and LTB4 increase with age [41,42], but there is
no information available at present on the influence of
age on the release of these eicosanoids from human alve-
olar macrophages. While there may be uncertainty about
the effect of age, we are able to compare the non-severe
with the severe group of asthmatic subjects as they were
of comparable age group.
In summary, we demonstrate impaired corticosteroid
modulation of the pro-inflammatory lipid mediator LTB4
but not of the anti-inflammatory lipoxin, LXA4, in AMs
of severe asthma. Together with the augmented LPS
induced formation of LTB4 and decreased generation of
LXA4 in severe asthma, our observations indicate a net
pro-inflammatory imbalance in severe asthma.
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